Shifting emphasis from pharmacogenomics to theragnostics
- 1 August 2006
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Biotechnology
- Vol. 24 (8), 942-946
- https://doi.org/10.1038/nbt0806-942
Abstract
What will be the role of theragnostic patents in upstream and downstream biomarker research?Keywords
This publication has 32 references indexed in Scilit:
- Decoding the research exemptionNature Reviews Genetics, 2006
- Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicinesExpert Opinion on Pharmacotherapy, 2006
- Policy Conflicts: Gene Patents and Health Care in CanadaPublic Health Genomics, 2005
- Excess in the pharmaceutical industryCMAJ : Canadian Medical Association Journal, 2004
- The myth of the biotech revolutionTrends in Biotechnology, 2004
- The Drugs Don't WorkSocial Studies of Science, 2003
- Don't mention the war...Nature, 2003
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- What Will Be the Role of Pharmacogenetics in Evaluating Drug Safety and Minimising Adverse Effects?Drug Safety, 2001
- Genset–Abbott deal heralds pharmacogenomics eraNature Biotechnology, 1997